Your browser doesn't support javascript.
loading
A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
Yih, W Katherine; Daley, Matthew F; Duffy, Jonathan; Fireman, Bruce; McClure, David; Nelson, Jennifer; Qian, Lei; Smith, Ning; Vazquez-Benitez, Gabriela; Weintraub, Eric; Williams, Joshua T B; Xu, Stanley; Maro, Judith C.
Affiliation
  • Yih WK; Harvard Pilgrim Health Care Institute and Department of Population Medicine, Harvard Medical School, Boston, MA, United States.
  • Daley MF; Kaiser Permanente Colorado, Aurora, CO, United States.
  • Duffy J; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Fireman B; Kaiser Permanente Northern California, Oakland, CA, United States.
  • McClure D; Marshfield Clinic Research Institute, Marshfield, WI, United States.
  • Nelson J; Kaiser Permanente Washington, Seattle, WA, United States.
  • Qian L; Kaiser Permanente Southern California, Pasadena, CA, United States.
  • Smith N; Kaiser Permanente Northwest, Portland, OR, United States.
  • Vazquez-Benitez G; HealthPartners Institute, Bloomington, MN, United States.
  • Weintraub E; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, United States.
  • Williams JTB; Denver Health, Denver, CO, United States.
  • Xu S; Kaiser Permanente Southern California, Pasadena, CA, United States.
  • Maro JC; Harvard Pilgrim Health Care Institute and Department of Population Medicine, Harvard Medical School, Boston, MA, United States.
Vaccine ; 41(3): 826-835, 2023 01 16.
Article in En | MEDLINE | ID: mdl-36535825
ABSTRACT

BACKGROUND:

Except for spontaneous reporting systems, vaccine safety monitoring generally involves pre-specifying health outcomes and post-vaccination risk windows of concern. Instead, we used tree-based data-mining to look more broadly for possible adverse events after Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccination.

METHODS:

Vaccine Safety Datalink enrollees receiving ≥1 dose of COVID-19 vaccine in 2020-2021 were followed for 70 days after Pfizer-BioNTech or Moderna and 56 days after Janssen vaccination. Incident diagnoses in inpatient or emergency department settings were analyzed for clustering within both the hierarchical ICD-10-CM code structure and the post-vaccination follow-up period. We used the self-controlled tree-temporal scan statistic and TreeScan software. Monte Carlo simulation was used to estimate p-values; p = 0.01 was the pre-specified cut-off for statistical significance of a cluster.

RESULTS:

There were 4.1, 2.6, and 0.4 million Pfizer-BioNTech, Moderna, and Janssen vaccinees, respectively. Clusters after Pfizer-BioNTech vaccination included (1) unspecified adverse effects, (2) common vaccine reactions, such as fever, myalgia, and headache, (3) myocarditis/pericarditis, and (4) less specific cardiac or respiratory symptoms, all with the strongest clusters generally after Dose 2; and (5) COVID-19/viral pneumonia/sepsis/respiratory failure in the first 3 weeks after Dose 1. Moderna results were similar but without a significant myocarditis/pericarditis cluster. Further investigation suggested the fifth signal group was a manifestation of mRNA vaccine effectiveness after the first 3 weeks. Janssen vaccinees had clusters of unspecified or common vaccine reactions, gait/mobility abnormalities, and muscle weakness. The latter two were deemed to have arisen from confounding related to practices at one site.

CONCLUSIONS:

We detected post-vaccination clusters of unspecified adverse effects, common vaccine reactions, and, for the mRNA vaccines, chest pain and palpitations, as well as myocarditis/pericarditis after Pfizer-BioNTech Dose 2. Unique advantages of this data mining are its untargeted nature and its inherent adjustment for the multiplicity of diagnoses and risk intervals scanned.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / COVID-19 Vaccines / COVID-19 / Myocarditis Limits: Humans Language: En Journal: Vaccine Year: 2023 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / COVID-19 Vaccines / COVID-19 / Myocarditis Limits: Humans Language: En Journal: Vaccine Year: 2023 Document type: Article Affiliation country: Estados Unidos